Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The round was co-led by MVM Partners, a healthcare growth equity investment firm, and Piper Sandler Merchant Banking, a commercial stage growth equity investment business of Piper Sandler Companies. The financing also included participation from an existing Series A investor.

The new financing will support Paragon 28’s ongoing initiatives to develop and launch new products, including the recently FDA cleared APEX 3DTM Total Ankle Replacement System, as well as continued commercial expansion in the US and international markets.

Albert DaCosta, President and CEO of Paragon 28, commented “We are pleased to add this capital to our balance sheet and equally excited about the partnership. The Series B proceeds will enable our team to focus on the best growth opportunities and expand our market position. To close this round on the tenth anniversary of the company is a special moment for our team.”

Kevin Cheng, a partner at MVM, noted “The foot and ankle segment of orthopedics is a relatively new surgical specialty. Paragon 28 is relentlessly focused on improving procedures through an extensive array of novel products that are specifically engineered for lower extremities. We are impressed by the advancements that the Paragon team has made, and we are delighted with the opportunity to support the business through its next phase of growth.”

Tom Schnettler, managing director with Piper Sandler Merchant Banking, added “The team at Paragon 28 has brought tremendous focus and innovation to the foot and ankle segment, an area of the orthopedics market that is growing rapidly and traditionally has been under-served. The company’s innovative solutions and extensive product line benefit surgeons and patients in addressing even the most difficult foot and ankle conditions. We are excited to partner with Paragon 28 and support the company’s mission to innovate and improve foot and ankle surgical outcomes.”

About Paragon 28, Inc.

Paragon 28, Inc. was established in 2010 to address the unmet and under-served needs of the foot and ankle community. From the onset, Paragon 28’s goal has been to re-invent the space of foot and ankle surgery. Through research and innovation, the company creates new and improved solutions to the challenges faced by foot and ankle specialists.

Latest news

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

CurvaFix Closes $39 Million Series C Financing Round Led by MVM Partners and Announces CEO Transition
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing
March 23, 2023

TEMPE, Ariz., March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients […]

OSSIO Launches World’s First and Only Non-Permanent Compression Staple
February 7, 2023

OSSIOfiber® Compression Staple Answers Surgeon, Patient Demand in Fastest Growing Product Category in Extremities WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation […]

VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
February 6, 2023

Second Generation GENOSYL® DS is the first and only Inhaled Nitric Oxide delivery system that is FDA-approved for rebreathing anesthesia, […]

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
January 9, 2023

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced […]

MVM Closes Oversubscribed Fund at $500 Million Hard Cap
November 14, 2022

BOSTON & LONDON — MVM Partners is pleased to announce the closing of its sixth healthcare fund, MVM VI, with […]

MVM Invests in Ossio
October 18, 2022

Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major […]